HRP20180221T1 - Novi sustav prijenosa lijeka zasnovan za jcv-vlp - Google Patents
Novi sustav prijenosa lijeka zasnovan za jcv-vlp Download PDFInfo
- Publication number
- HRP20180221T1 HRP20180221T1 HRP20180221TT HRP20180221T HRP20180221T1 HR P20180221 T1 HRP20180221 T1 HR P20180221T1 HR P20180221T T HRP20180221T T HR P20180221TT HR P20180221 T HRP20180221 T HR P20180221T HR P20180221 T1 HRP20180221 T1 HR P20180221T1
- Authority
- HR
- Croatia
- Prior art keywords
- vlp
- use according
- drug
- pharmaceutical preparation
- cns
- Prior art date
Links
- 238000012377 drug delivery Methods 0.000 title 1
- 239000003814 drug Substances 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 230000008499 blood brain barrier function Effects 0.000 claims 3
- 210000001218 blood-brain barrier Anatomy 0.000 claims 3
- 208000015114 central nervous system disease Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 241000701460 JC polyomavirus Species 0.000 claims 1
- 241001505332 Polyomavirus sp. Species 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22041—Use of virus, viral particle or viral elements as a vector
- C12N2710/22042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22041—Use of virus, viral particle or viral elements as a vector
- C12N2710/22043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24071—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (15)
1. VLP izveden iz humanog polioma virusa koji sadrži lijek za upotrebu u metodi liječenja terapijom ili metodom in vivo dijagnoze CNS bolesti.
2. VLP za uporabu u skladu s patentnim zahtjevom 1, naznačen time što je VLP izveden iz JCV.
3. VLP za uporabu u skladu s patentnim zahtjevom 1 ili 2, dok VLP prelazi krvno-moždanu barijeru za ulazak u CNS zajedno s lijekom koji je enkapsuliran VLP-om.
4. VLP za uporabu u skladu s najmanje jednim od gore navedenih zahtjeva, dok VLP koji sadrži lijek prolazi fiziološki intaktnu barijeru krvi-mozak.
5. VLP za upotrebu prema najmanje jednim od gore navedenih zahtjeva, dok je bolest CNS neurološki, neuronski ili neurodegenerativni poremećaj.
6. VLP za uporabu prema najmanje jednim od gore navedenih zahtjeva, dok je VLP sastavljen od VP1 proteina JC virusa.
7. VLP za upotrebu u skladu s najmanje jednim od gore navedenih zahtjeva, a VLP se primjenjuje putem koje dopušta lijek.
8. VLP za uporabu prema najmanje jednim od gore navedenih zahtjeva, dok se VLP primjenjuje intravenozno.
9. VLP za upotrebu u skladu s najmanje jednim od gore navedenih zahtjeva, dok VLP sadrži VP1 i / ili VP2, gdje prema SEQ ID N0: 1 preko njegove cijele duljine i / ili gdje VP2 sadrži aminokiselinsku sekvencu koja je najmanje 80% identično aminokiselinskoj sekvenci prema SEQ ID NO: 3 u cijeloj svojoj dužini.
10. VLP za uporabu u skladu s najmanje jednim od gore navedenih zahtjeva, dok se lijek odabire iz skupine koja se sastoji od posebno odabranog iz skupine koju čine nukleinske kiseline koje kodiraju željeni protein kao što je mRNA, cDNA, plazmid ili ribozim.
11. VLP za upotrebu prema najmanje jednim od gore navedenih zahtjeva, dok je VLP napunjen lijekom.
12. Farmaceutski pripravak namijenjen uporabi u postupku liječenja terapijom ili metodom in vivo dijagnosticiranja bolesti CNS, dok farmaceutski sastav sadrži VLP prema bilo kojem od gore navedenih zahtjeva, pri čemu najmanje 1%, poželjno najmanje 15% , poželjnije najmanje 50%, naročito poželjno najmanje 95% ukupne količine lijeka potpuno je enkapsulirano u trup VLP-a
13. Farmaceutski pripravak namijenjen uporabi u skladu s patentnim zahtjevom 12, naznačen time što VLP nisu agregatni.
14. Farmaceutski pripravak namijenjen uporabi u skladu s patentnim zahtjevima 12 ili 13, naznačen time, da se farmaceutski pripravak daje intravenski.
15. Farmaceutski pripravak namijenjen uporabi u skladu s najmanje jednim od patentnih zahtjeva 12 do 14, naznačen time što prelazi i / ili VLP krvno-moždanu barijeru za ulazak u CNS zajedno s lijekom koji je enkapsuliran VLP-om.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12001507.8A EP2636746A1 (en) | 2012-03-06 | 2012-03-06 | A novel drug delivery system based on JCV-VLP |
| PCT/EP2013/000656 WO2013131644A1 (en) | 2012-03-06 | 2013-03-06 | A novel drug delivery system based on jcv-vlp |
| EP13714195.8A EP2823048B1 (en) | 2012-03-06 | 2013-03-06 | A novel drug delivery system based on jcv-vlp |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180221T1 true HRP20180221T1 (hr) | 2018-04-20 |
Family
ID=48047958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180221TT HRP20180221T1 (hr) | 2012-03-06 | 2018-02-06 | Novi sustav prijenosa lijeka zasnovan za jcv-vlp |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US20150045417A1 (hr) |
| EP (3) | EP2636746A1 (hr) |
| JP (1) | JP6175080B2 (hr) |
| KR (1) | KR102058488B1 (hr) |
| CN (1) | CN104395475B (hr) |
| AU (1) | AU2013230232B2 (hr) |
| BR (1) | BR112014021497A2 (hr) |
| CA (1) | CA2865564C (hr) |
| CY (1) | CY1120150T1 (hr) |
| DK (2) | DK2823048T3 (hr) |
| EA (1) | EA035308B1 (hr) |
| ES (2) | ES2658941T3 (hr) |
| HK (1) | HK1208046A1 (hr) |
| HR (1) | HRP20180221T1 (hr) |
| HU (2) | HUE038284T2 (hr) |
| LT (1) | LT2823048T (hr) |
| MX (1) | MX354004B (hr) |
| NO (1) | NO2823048T3 (hr) |
| NZ (1) | NZ629255A (hr) |
| PL (1) | PL2823048T3 (hr) |
| PT (2) | PT2823048T (hr) |
| SG (3) | SG10202102293QA (hr) |
| SI (1) | SI2823048T1 (hr) |
| TR (1) | TR201802849T4 (hr) |
| WO (1) | WO2013131644A1 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3031821A1 (en) * | 2014-12-08 | 2016-06-15 | Life Science Inkubator | polyomavirus VLPs with a fusion protein |
| EP3031820A1 (en) * | 2014-12-08 | 2016-06-15 | Life Science Inkubator | JC Polyomavirus VLP (virus-like particle) with a targeting peptide |
| EP3368694A1 (en) * | 2015-10-28 | 2018-09-05 | Life Science Inkubator GmbH | Use of vlp for the detection of nucleic acids |
| CN106048093A (zh) * | 2016-08-02 | 2016-10-26 | 北京思尔成生物技术有限公司 | Jc病毒的检测方法、试剂盒及其应用 |
| EP3670652A1 (en) * | 2018-12-18 | 2020-06-24 | NEUWAY Pharma GmbH | Vlp for the treatment of a lysosomal storage disease |
| CA3049197C (en) * | 2018-12-18 | 2023-01-03 | Neuway Pharma Gmbh | A drug delivery system comprising virus-like particles from john cunningham virus and methods providing thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19543553B4 (de) | 1995-11-22 | 2009-04-09 | Deutsches Primatenzentrum Gmbh | VP-Antigene des JC-Virus |
| EP0977596B1 (en) | 1997-04-26 | 2004-01-21 | Rpms Technology Limited | Use of papovavirus capsid protein for delivery of therapeutic agents to neuronal cells |
| DE19916224C1 (de) | 1999-04-10 | 2000-06-21 | November Ag Molekulare Medizin | Synthetisches biologisch aktives Molekül |
| DE10131145B4 (de) | 2001-06-28 | 2005-07-14 | Innovent E.V. | Zusammensetzung zum zellspezifischen Transfer von Wirkstoffen |
| US7612039B2 (en) * | 2002-06-12 | 2009-11-03 | Temple University - Of The Commonwealth System Of Higher Education | Method of cell growth inhibition with agnoprotein |
| EP2036980A1 (de) | 2007-09-14 | 2009-03-18 | Gruber, Jens | Herabregulation der Genexpression mittels Nukleinsäure-beladener virusähnlicher Partikel |
| EP2093780B1 (en) | 2008-02-22 | 2014-11-05 | ABB Technology AG | A spring drive unit, an operating device for an electrical switching apparatus, and method for charging and/or discharging a spring in an operating device for an electrical switching apparatus |
| CN102369436B (zh) * | 2009-02-05 | 2014-10-22 | 生物基因Idecma公司 | 用于检测jc多瘤病毒的方法 |
-
2012
- 2012-03-06 EP EP12001507.8A patent/EP2636746A1/en not_active Withdrawn
-
2013
- 2013-03-06 HU HUE13714195A patent/HUE038284T2/hu unknown
- 2013-03-06 ES ES13714195.8T patent/ES2658941T3/es active Active
- 2013-03-06 SG SG10202102293QA patent/SG10202102293QA/en unknown
- 2013-03-06 LT LTEP13714195.8T patent/LT2823048T/lt unknown
- 2013-03-06 SG SG10201607358WA patent/SG10201607358WA/en unknown
- 2013-03-06 JP JP2014560272A patent/JP6175080B2/ja active Active
- 2013-03-06 EP EP17200325.3A patent/EP3299468A1/en not_active Withdrawn
- 2013-03-06 SG SG11201405255SA patent/SG11201405255SA/en unknown
- 2013-03-06 EP EP13714195.8A patent/EP2823048B1/en active Active
- 2013-03-06 KR KR1020147028123A patent/KR102058488B1/ko active IP Right Grant
- 2013-03-06 BR BR112014021497A patent/BR112014021497A2/pt not_active IP Right Cessation
- 2013-03-06 DK DK13714195.8T patent/DK2823048T3/en active
- 2013-03-06 US US14/383,267 patent/US20150045417A1/en not_active Abandoned
- 2013-03-06 CN CN201380013112.4A patent/CN104395475B/zh active Active
- 2013-03-06 SI SI201330942T patent/SI2823048T1/en unknown
- 2013-03-06 MX MX2014010651A patent/MX354004B/es active IP Right Grant
- 2013-03-06 PT PT137141958T patent/PT2823048T/pt unknown
- 2013-03-06 NO NO13714195A patent/NO2823048T3/no unknown
- 2013-03-06 AU AU2013230232A patent/AU2013230232B2/en not_active Ceased
- 2013-03-06 PL PL13714195T patent/PL2823048T3/pl unknown
- 2013-03-06 EA EA201491636A patent/EA035308B1/ru unknown
- 2013-03-06 NZ NZ629255A patent/NZ629255A/en not_active IP Right Cessation
- 2013-03-06 WO PCT/EP2013/000656 patent/WO2013131644A1/en active Application Filing
- 2013-03-06 CA CA2865564A patent/CA2865564C/en active Active
- 2013-03-22 DK DK13001491.3T patent/DK2774991T3/en active
- 2013-03-22 ES ES13001491.3T patent/ES2661389T3/es active Active
- 2013-03-22 HU HUE13001491A patent/HUE038580T2/hu unknown
- 2013-03-22 PT PT130014913T patent/PT2774991T/pt unknown
- 2013-03-22 TR TR2018/02849T patent/TR201802849T4/tr unknown
-
2015
- 2015-08-31 HK HK15108461.6A patent/HK1208046A1/xx not_active IP Right Cessation
-
2018
- 2018-02-05 CY CY20181100133T patent/CY1120150T1/el unknown
- 2018-02-06 HR HRP20180221TT patent/HRP20180221T1/hr unknown
- 2018-06-26 US US16/018,110 patent/US20180296700A1/en not_active Abandoned
-
2019
- 2019-03-15 US US16/354,739 patent/US11291735B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180221T1 (hr) | Novi sustav prijenosa lijeka zasnovan za jcv-vlp | |
| Liu et al. | Brain-targeted co-delivery of therapeutic gene and peptide by multifunctional nanoparticles in Alzheimer's disease mice | |
| EP3043785B1 (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| HRP20171165T1 (hr) | Genska terapija za lizosomske bolesti nakupljanja | |
| JP2016516016A5 (hr) | ||
| JP2014526441A5 (hr) | ||
| HRP20211453T1 (hr) | Liječenje amd uporabom aav sflt-1 | |
| TWI581801B (zh) | 治療血管新生相關之眼疾之組合物及方法 | |
| JP2012041342A5 (hr) | ||
| MX2017012506A (es) | Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan. | |
| RU2011149094A (ru) | Генная терапия нейродегенеративных нарушений | |
| SI2625199T1 (en) | Procedures for treating psoriasis using IL-17 antagonists | |
| JP2015522264A5 (hr) | ||
| JP2016518411A (ja) | プールされた免疫グロブリンｇを用いたアルツハイマー病の亜集団の治療 | |
| JP2015532293A5 (ja) | 糖尿病患者における心不全の治療用組成物 | |
| HRP20180071T4 (hr) | Upotreba kladribina u liječenju očnog neuromijelitisa | |
| JP2017507655A5 (hr) | ||
| Fukuda et al. | Quantitative analysis of inulin distribution in the brain focused on nose-to-brain route via olfactory epithelium by reverse esophageal cannulation | |
| JP2015514115A5 (hr) | ||
| RU2017107033A (ru) | Способы лечения депрессии с применением модуляторов nmda | |
| JP2017519763A5 (hr) | ||
| JP2013544245A5 (ja) | ネプリライシンの発現および活性を増大させるための医薬組成物 | |
| JP2017512194A5 (hr) | ||
| HRP20171993T1 (hr) | Varijante ljudskog gdnf | |
| Casaca-Carreira et al. | Distribution and penetration of intracerebroventricularly administered 2′ OMePS oligonucleotide in the mouse brain |